Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Citi |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2014-01-23 12:35:55 |
Versijas komentārs | |
Teksts |
Olaine, January 23, 2014
„Olainfarm”
Has Increased Its Sales Of Meldonium By 250% In Three
Years
AS “Olainfarm”
confirms that Chamber of Civil cases of the Supreme Court of Latvia
in its ruling has partially satisfied the claim by AS
„Grindeks”
to cancel the
registration of trade marks MIDOLAT
and
МИДОЛАТ.
Therefore it is now an obligation of
AS
„Olainfarm” to destroy all the medicines and packaging, on which a
graphic designation of Mildronāts, MIDOLAT and
МИДОЛАТ. This has to be completed
within one year after the ruling takes effect.
AS „Olainfarm” does not produce either medicines or packaging with
such designations since 2010, therefore this obligation poses no
impact on performance of financial state of the company.
„Respecting worries of „Grindeks” about the trade mark of its
flagship product, we have been producing and selling meldonium
under trade marks of „Vazonat”, „Vazomag”, ”Zovanat” and „Meldonium
Olainfarm” for three years now,” says Salvis Lapins, Member of the
Board of AS „Olainfarm”. „We have registered trade marks on this
metabolic medicine in 27 differrent countries. Sales and
production volumes of this product have grown by 250% over the last
three years making it s stable participant of our top 15 products
team”.
A/s OlainFarm is one of the
biggest pharmaceutical companies in Latvia with 40 years of
experience in production of medication and chemical and
pharmaceutical products. A basic principle of company's operations
is to produce reliable and effective top quality products for
Latvia and the rest of the world. Products made by the Group are
being exported to more than 30 countries of the world, including
the Baltics, Russia, other CIS, Europe, Asia, North America and
Australia. Information
prepared by:
|
Pielikumi |
|